ATE432947T1 - Menschliche antikörper als detektionsreagenzien - Google Patents

Menschliche antikörper als detektionsreagenzien

Info

Publication number
ATE432947T1
ATE432947T1 AT00983939T AT00983939T ATE432947T1 AT E432947 T1 ATE432947 T1 AT E432947T1 AT 00983939 T AT00983939 T AT 00983939T AT 00983939 T AT00983939 T AT 00983939T AT E432947 T1 ATE432947 T1 AT E432947T1
Authority
AT
Austria
Prior art keywords
human antibodies
detection reagents
methods
human
hama
Prior art date
Application number
AT00983939T
Other languages
English (en)
Inventor
Joe Buechler
Gunars Valkirs
Jeff Gray
Nils Lonberg
Original Assignee
Biosite Inc
Genpharm Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23811375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE432947(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosite Inc, Genpharm Int filed Critical Biosite Inc
Application granted granted Critical
Publication of ATE432947T1 publication Critical patent/ATE432947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00983939T 1999-12-06 2000-12-06 Menschliche antikörper als detektionsreagenzien ATE432947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/456,090 US6680209B1 (en) 1999-12-06 1999-12-06 Human antibodies as diagnostic reagents
PCT/US2000/033042 WO2001040306A1 (en) 1999-12-06 2000-12-06 Human antibodies as detection reagents

Publications (1)

Publication Number Publication Date
ATE432947T1 true ATE432947T1 (de) 2009-06-15

Family

ID=23811375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983939T ATE432947T1 (de) 1999-12-06 2000-12-06 Menschliche antikörper als detektionsreagenzien

Country Status (9)

Country Link
US (3) US6680209B1 (de)
EP (1) EP1237926B1 (de)
JP (1) JP2003530543A (de)
AT (1) ATE432947T1 (de)
AU (1) AU781736B2 (de)
CA (1) CA2392729A1 (de)
DE (1) DE60042342D1 (de)
GB (1) GB2374415B (de)
WO (1) WO2001040306A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (de) * 2002-02-20 2006-04-26 Dyax Corp Mhc-peptid-komplexbindende liganden
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
US20040132141A1 (en) * 2002-08-28 2004-07-08 Kimon Angelides Selecting therapeutic human monoclonal antibodies from disease-specific libraries
AU2003299641C1 (en) * 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
AU2005316844A1 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US7396689B2 (en) * 2005-02-04 2008-07-08 Decision Biomarkers Incorporated Method of adjusting the working range of a multi-analyte assay
EP1874820A4 (de) * 2005-04-20 2010-09-22 Amgen Fremont Inc Hochaffine, vollständig humane monoklonale antikörper gegen interleukin-8 und epitope für solche antikörper
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
ZA200810677B (en) * 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008106648A2 (en) * 2007-03-01 2008-09-04 Abbott Laboratories Immunoassays exhibiting a reduction in prozone phenomena
SG196697A1 (en) 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
WO2009086411A2 (en) * 2007-12-27 2009-07-09 Abbott Laboratories Negative mimic antibody for use as a blocking reagent in bnp immunoassays
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
EP2297200A1 (de) * 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti-influenza-antikörper und anwendungen davon
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
EP2636513B1 (de) * 2008-04-10 2014-08-27 Stratasys Ltd. System und Verfahren für dreidimensionalen Modelldruck
SE533515C2 (sv) 2008-04-16 2010-10-12 Aamic Ab Analysförfarande för samtidig analys av flera analyter
JPWO2009148150A1 (ja) * 2008-06-06 2011-11-04 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102712945B (zh) 2009-08-18 2016-11-02 哈佛大学校长及研究员协会 治疗增殖性疾病和病原性疾病的方法和组合物
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
KR101881714B1 (ko) 2009-10-26 2018-07-24 네스텍 소시에테아노님 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
JP6022441B2 (ja) 2010-04-30 2016-11-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
DK3228631T3 (da) * 2011-06-13 2020-09-28 Tla Targeted Immunotherapies Ab Behandling af respiratoriske tilstande
EP3130921B1 (de) 2011-07-06 2018-09-12 Nestec S.A. Tests für den nachweis neutralisierender autoantikörper gegen biologische therapie mit tnf-alpha
US9220733B2 (en) 2012-03-19 2015-12-29 The Regents Of The University Of California Solubilization of antigen components for removal from tissues
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
CA2892818A1 (en) 2012-11-28 2014-06-05 Abwiz Bio, Inc. Preparation of gene-specific templates for the use in single primer amplification
US20140212987A1 (en) * 2013-01-30 2014-07-31 Siemens Healthcare Diagnostics Inc. Signal Ratio in Assay Calibrators
US10895571B2 (en) * 2013-06-06 2021-01-19 Siemens Healthineers Nederland B.V. Reagents, methods and devices to prevent aggregation in particle based tests for the detection of multimeric target molecules
EP3536705A1 (de) 2014-12-05 2019-09-11 Société des Produits Nestlé S.A. Isoliertes lösliches alpha-4 integrin, beta-7 intergrin und alpha-4/beta-7 heterodimer integrin
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
KR20170137111A (ko) * 2015-04-17 2017-12-12 알사니스 바이오사이언시스 게엠베하 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체
US11899020B2 (en) 2017-03-31 2024-02-13 The Regents Of The University Of California Shotgun proteomic antigen identification
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
EP4097144A4 (de) * 2020-01-28 2024-02-28 University of Southern California Genom-engineering des menschlichen immunglobulin-locus zur expression rekombinanter bindungsdomänenmoleküle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0063810B1 (de) * 1981-04-29 1986-03-05 Ciba-Geigy Ag Prüfmittel und Ausrüstung für immunologische Analysen
US4514505A (en) * 1982-05-21 1985-04-30 The Trustees Of Columbia University In The City Of New York Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DK169582B1 (da) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5914241A (en) 1993-01-19 1999-06-22 Biosite Diagnostics, Inc. Assays and kits for detecting analytes in the presence of cross-reacting substances
WO1994026787A1 (en) 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
EP0724651B1 (de) * 1993-10-19 2008-08-20 The Scripps Research Institute Synthetische humane neutralisierende monoklonale antikörper gegen hiv
PT744958E (pt) * 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
JPH07260786A (ja) * 1994-03-18 1995-10-13 Tosoh Corp ヒト由来一定領域を有する抗体を使用する免疫測定方法
AU2823895A (en) * 1994-06-09 1996-01-04 Bar-Ilan University Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions
EP0822830B1 (de) 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0985033A4 (de) * 1997-04-04 2005-07-13 Biosite Inc Polyvalente und polyklonale bibliotheken
EP0934953A2 (de) 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Komplexspezifische Antikörper, Verfahren zur Herstellung und deren Verwendungen
US5939807A (en) 1997-12-16 1999-08-17 Reliance Electric Industrial Company Cap mounted drive for a brushless DC motor
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies

Also Published As

Publication number Publication date
AU2063001A (en) 2001-06-12
AU781736B2 (en) 2005-06-09
US20030165993A1 (en) 2003-09-04
EP1237926A4 (de) 2006-04-12
US20080039338A1 (en) 2008-02-14
WO2001040306A9 (en) 2002-05-30
GB2374415B (en) 2004-12-29
WO2001040306A1 (en) 2001-06-07
US6680209B1 (en) 2004-01-20
CA2392729A1 (en) 2001-06-07
GB0215302D0 (en) 2002-08-14
EP1237926B1 (de) 2009-06-03
JP2003530543A (ja) 2003-10-14
GB2374415A (en) 2002-10-16
DE60042342D1 (de) 2009-07-16
EP1237926A1 (de) 2002-09-11
US7189515B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
GB2374415B (en) Human antibodies as detection reagents
DE602004024236D1 (en) Assay
WO2005003767A3 (en) Elemental analysis of tagged biologically active materials
AU2002304640A1 (en) Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
MX2009004460A (es) Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos.
ATE317122T1 (de) Fluoreszierende polarisation
TW370614B (en) Oligomerized antibodies, method of immunological determination using the same and reagent kit comprising the same
DE60019111D1 (de) Verfahren zur zellseparation unter verwendung von immunorosetten
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
WO1999022242A3 (en) Measurement of glycated hemoglobin
WO2004101769A3 (en) Proteins, sensors, and methods of characterizing analytes using the same
KR960029789A (ko) 생체내 물질의 면역학적 분석용 키트 및 면역학적 분석 방법
WO2002001230A3 (en) Rapid and sensitive detection of protein aggregation
ATE310956T1 (de) Festphasenverfahren und testsatz zur antigen- und antikörperprüfung in der blutgruppen-serologie
DK0544869T3 (da) Immunologisk analysemetode til bestemmelse af antistoffer i biologiske væsker, og et analytisk kit t il gennemførelse heraf
AU2003260457A1 (en) A method and kit for the quantitative and/or qualitative detection of components in a sample
FI861358A0 (fi) Monoklonala antikroppar foer determinering av glykosylerat hemoglobin i blodet.
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
HUP9800225A2 (hu) Eljárás és vegyületek analitok meghatározására remanenciaméréssel és ezek alkalmazásai
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
DE60137078D1 (de) Elementaranalytik von markierten biologisch aktiven substanzen
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
DE59903720D1 (de) Rezeptorbindungsassays und reagenziensatz zum nachweis von tsh-rezeptor-autoantikörpern
CN208580108U (zh) 一种抗缪勒管激素免疫层析定量检测试纸条

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties